Related Experiment Video

Updated: Jul 16, 2026

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
10:44

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

Nifuratel-containing initial anti-Helicobacter pylori triple therapy in children

Alexander A Nijevitch1, Valery U Sataev, Elsa N Akhmadeyeva

  • 1Children's Republican Hospital, Ufa, Russia. aanj@rambler.ru

Helicobacter
|February 21, 2007
PubMed

Insights

A new triple therapy using nifuratel, amoxicillin, and bismuth subcitrate effectively eradicated Helicobacter pylori in children. This regimen demonstrated high efficacy and good tolerability for pediatric H. pylori gastritis treatment.

Area of Science:

  • Pediatric Gastroenterology
  • Infectious Diseases
  • Microbiology

Background:

  • Standard Helicobacter pylori treatment in children, proton pump inhibitor-based triple therapy with amoxicillin and metronidazole, shows low eradication rates in Russia.
  • Effective and tolerable treatment options for pediatric H. pylori infections are crucial.

Purpose of the Study:

  • To assess the efficacy and tolerability of an empiric triple therapy regimen comprising nifuratel, amoxicillin, and bismuth subcitrate for childhood H. pylori gastritis.

Main Methods:

  • Seventy-three pediatric patients with H. pylori-associated chronic gastritis received a 10-day course of bismuth subcitrate, nifuratel, and amoxicillin.
  • H. pylori status was confirmed via modified Giemsa staining before and 4-6 weeks after treatment.

Main Results:

  • The triple therapy achieved an 86% H. pylori eradication rate (95% CI: 76.6-93.2) in pediatric patients.
  • No serious adverse events were reported, and all mild side effects were self-limiting, leading to no treatment withdrawals.

Conclusions:

  • Nifuratel, bismuth subcitrate, and amoxicillin combination therapy is an effective and well-tolerated treatment for H. pylori eradication in children.
  • This regimen offers a promising alternative for managing H. pylori infections in pediatric populations, particularly where standard therapies are less effective.
Abstract

More Related Videos

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology03:33

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology

Published on: May 23, 2025

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...